Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ECYT

Endocyte (ECYT) Stock Price, News & Analysis

Endocyte logo

About Endocyte Stock (NASDAQ:ECYT)

Advanced Chart

Key Stats

Today's Range
$23.99
$23.99
50-Day Range
N/A
52-Week Range
$2.81
$24.00
Volume
N/A
Average Volume
2.12 million shs
Market Capitalization
$1.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.

Receive ECYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endocyte and its competitors with MarketBeat's FREE daily newsletter.

ECYT Stock News Headlines

Telix Pharmaceuticals Ltd (TLX)
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More Headlines

ECYT Stock Analysis - Frequently Asked Questions

Endocyte, Inc. (NASDAQ:ECYT) issued its quarterly earnings data on Wednesday, November, 7th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. The biopharmaceutical company earned $0.09 million during the quarter, compared to analyst estimates of $0.02 million. Endocyte had a negative trailing twelve-month return on equity of 21.19% and a negative net margin of 32,296.09%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Endocyte investors own include Bristol-Myers Squibb (BMY), Meta Platforms (META), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Micron Technology (MU), Netflix (NFLX) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/07/2018
Today
6/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ECYT
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$55.06 million
Net Margins
-32,296.09%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$70,000.00
Price / Sales
28,133.42
Price / Cash Flow
N/A
Book Value
$1.99 per share
Price / Book
12.06

Miscellaneous

Free Float
N/A
Market Cap
$1.97 billion
Optionable
Optionable
Beta
-0.01
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:ECYT) was last updated on 6/3/2025 by MarketBeat.com Staff
From Our Partners